SCHEMBL19686589

SCHEMBL19686589

Cc1cc(C)n(-c2nc(NC3CCC(F)(F)C3)cc(C(F)F)n2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN3 Q9UGI6 2/20 0.52
KCNN2 Q9H2S1 1/20 0.52
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
IDH1 O75874 2/20 0.41
ALOX15 P16050 2/20 0.40
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686933 0.94 KCNN2 (0.57) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL19686510 0.91 KCNN2 (0.51) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL19686938 0.88 KCNN3 (0.67) KCNN3KCNN2ALDH1A1ALOX15LMNA
SCHEMBL21144006 0.85 KCNN2 (0.54) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL19686504 0.85 KCNN2 (0.54) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL19686506 0.85 KCNN2 (0.54) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL19686502 0.85 KCNN2 (0.54) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL19686315 0.84 KCNN2 (0.56) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL21143991 0.84 KCNN3 (0.56) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1
SCHEMBL19686314 0.84 KCNN2 (0.56) KCNN3KCNN2CYP1A2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN3 11/4885KCNN2 5/4885CYP1A2 1148/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN3 11/4885KCNN2 5/4885CYP1A2 1148/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN3 11/4885KCNN2 5/4885CYP1A2 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.